Last-Resort drug access opens for rare tumor patients
NCT ID NCT05028166
First seen Apr 07, 2026 · Last updated May 14, 2026 · Updated 4 times
Summary
This program provides mirdametinib to individual patients with severe, life-threatening conditions like NF1-related tumors or MAP-K pathway diseases who have no other treatment options and cannot join a clinical trial. Each case requires approval from the company, ethics board, and health authorities. The goal is to offer a potential treatment when all standard options have failed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HISTIOCYTIC NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.